Related by context. All words. (Click for frequent words.) 81 Long Term Efficacy 77 Well Tolerated 77 Patients Treated 76 Antitumor Activity 76 Antiviral Activity 76 Monotherapy 75 Capecitabine 75 Meets Primary Endpoint 75 Study Evaluating 75 Peginterferon 75 Clinical Trial Results 75 Tiotropium 75 Pediatric Patients 75 Patients Receiving 74 Relapsing Multiple Sclerosis 74 Immunogenicity 74 Elderly Patients 74 Survival Benefit 74 Statistically Significant 74 Previously Treated 74 Chronic Hepatitis C 74 Pharmacokinetics PK 74 Oral Fingolimod 74 Pooled Analysis 73 Pharmacokinetic Study 73 Newly Diagnosed Multiple Myeloma 73 Anti Tumor Activity 73 Efficacy 73 Demonstrated Significant 73 Patients Treated With 73 Phase 2b Study 73 Demonstrates Positive 73 Investigational Compound 73 Safety Tolerability 73 Combination Therapy 73 Phase IIb Trial 72 Demonstrates Efficacy 72 Potent Antiviral Activity 72 Adjunctive Therapy 72 Renal Cell Carcinoma 72 Orally Active 72 Partial Onset Seizures 72 Is Well Tolerated 72 Phase III Trial 72 Demonstrates Potent 72 Unfractionated Heparin 72 Peginterferon Alfa 2a 72 Combination Treatment 72 Efficacy Results 72 Refractory Hodgkin Lymphoma 72 Controlled Trial 71 Improves Outcomes 71 Dose Escalation 71 Relapsed Refractory 71 Enoxaparin 71 Advanced Melanoma 71 Sustained Efficacy 71 Adalimumab 71 Clinical Efficacy 71 Overactive Bladder 71 Investigational Drug 71 Drug Candidate 71 Metastatic Colorectal Cancer 71 Phase 2b Clinical Trial 71 Platelet Inhibition 71 Shows Efficacy 71 Disease Progression 71 Controlled Study 71 Hormone Refractory Prostate Cancer 71 Acute Ischemic Stroke 71 Metastatic Prostate Cancer 71 Epoetin Alfa 71 Prolongs Survival 71 Efficacious 71 Improves Survival 71 II Clinical Trial 71 Rheumatoid Arthritis Patients 71 Inhaled Corticosteroids 71 Pivotal Phase III 71 Kidney Function 71 Plus Ribavirin 71 Pharmacokinetic 71 Postmenopausal Women 70 JAK Inhibitor 70 Subgroup Analysis 70 Adjuvant Treatment 70 Low Dose 70 Investigational Treatment 70 Phase 2a Clinical Trial 70 Randomized Double Blind 70 Patients Undergoing 70 Pharmacodynamics 70 Hypercholesterolemia 70 Phase IIa Clinical Trial 70 Single Dose 70 Previously Untreated 70 Phase III Clinical Trial 70 Relapsing Remitting Multiple Sclerosis 70 Bivalirudin 70 Relapsed Multiple Myeloma 70 Treatment Naïve Patients 70 Pegylated Interferon 70 Preclinical Data 70 Advanced Prostate Cancer 70 Double Blind Placebo 70 Fixed Dose 70 Pivotal Phase 70 Statin Therapy 70 Improved Survival 70 Insulin Glargine 70 Adjuvant Therapy 70 Study Showed 70 Combo Therapy 70 Hypertensive Patients 70 Protease Inhibitor 70 Treatment Naive HIV 70 Zoledronic Acid 69 Phase IIb Clinical Trial 69 Treated Patients 69 Extended Release 69 ritonavir boosted 69 Trial Evaluating 69 Melphalan 69 Knee Osteoarthritis 69 Autologous Stem Cell Transplantation 69 Dose Response 69 Novel Oral 69 Versus Placebo 69 Vildagliptin 69 Androgen Deprivation Therapy 69 Pemetrexed 69 Parathyroid Hormone 69 Intravitreal 69 Bevacizumab 69 Anticancer Activity 69 Double Blind Randomized 69 Anti Tumor 69 Glucose Control 69 Heart Failure Patients 69 Fluorouracil 69 Clinical Trial Evaluating 69 Medoxomil 69 Darbepoetin Alfa 69 Phase 2b Trial 69 Pharmacokinetics 69 Appears Safe 69 Pioglitazone 69 Aliskiren 69 Fracture Risk 69 Hepatitis C Patients 69 Demonstrates Significant 69 Metastatic Pancreatic Cancer 68 Venous Thromboembolism 68 Infected Patients 68 Metastatic Renal Cell Carcinoma 68 Adefovir 68 Glatiramer Acetate 68 Hepatitis C Genotype 68 Benign Prostatic Hyperplasia 68 Presents Preclinical Data 68 Diffuse Large B 68 Receptor Antagonist 68 Treating Chronic 68 Nilotinib 68 Randomized Double blind 68 Universal Flu Vaccine 68 Meta Analysis 68 Tezampanel 68 HER2 Positive Breast Cancer 68 Randomized Placebo Controlled Trial 68 Treatment Regimen 68 Advanced Colorectal Cancer 68 Colorectal Cancer Patients 68 Significantly Reduced 68 Cutaneous T 68 Placebo Controlled Trial 68 Interferon Beta 68 Peginterferon Alfa 2b 68 Prospective Randomized 68 oral prodrug 68 Diabetic Neuropathy 68 Solid Tumors 68 Transdermal Patch 68 Natalizumab 68 Chronic Sinusitis 68 Randomized Phase 68 Diabetic Patients 68 Metastatic Melanoma 68 Placebo Controlled Study 68 Complicated Skin 68 Protease Inhibitors 68 FOLFOX6 68 Clinical Outcome 68 Denufosol 68 Malignant Glioma 68 ISTODAX ® 68 Cardiovascular Events 68 Fungal Infections 68 zonisamide SR 68 Breast Cancer Recurrence 68 Investigational Agent 68 Resistant Hypertension 68 Advanced Solid Tumors 67 Completes Patient Enrollment 67 Decitabine 67 Soft Tissue Sarcoma 67 Multiple Myeloma Patients 67 Renal Function 67 Bone Mineral Density 67 Advanced Renal Cell 67 Cardiotoxicity 67 Bare Metal Stents 67 Regimens 67 Clopidogrel 67 Inhalation Solution 67 Interferon beta 1a 67 Cholesterol Lowering Drug 67 Polymerase Inhibitor 67 Nebulized 67 Myeloma Patients 67 Myelodysplastic Syndromes 67 Naive Patients 67 Ranolazine 67 Hsp# Inhibitor 67 HCV Protease Inhibitor 67 Pivotal Trial 67 ACE Inhibitors 67 Treatment Naive Patients 67 Lacosamide 67 Tolerability Study 67 Kidney Transplant Patients 67 Novel Mechanism 67 Study Demonstrates 67 8mg/kg 67 FDA Approvals 67 Bortezomib 67 Pivotal Study 67 Adjuvant Chemotherapy 67 tolerability profiles 67 HCV Genotype 67 PRN FDA Approves 67 Shows Promising 67 Phase 2a Trial 67 Phase III Trials 67 Posaconazole 67 alfa 2a 67 Pegylated 67 Fondaparinux 67 Erlotinib 67 Paraplatin ® 67 Lenalidomide 67 Non Inferiority 67 Randomized Double Blind Placebo 67 Improve Survival 67 TO AVOID PREGNANCY WHILE 67 Mouse Model 67 Cyclophosphamide 67 Randomized Clinical Trial 67 Preclinical Study 67 Stent Implantation 67 Anticoagulant 67 Sulfonylurea 67 Recombinant Human 67 Renal Impairment 67 Glufosfamide 67 limiting toxicity DLT 67 Risedronate 67 Presents Positive 67 Completes Enrollment 67 See CLINICAL PHARMACOLOGY 67 NDA Submission 67 pan HDAC inhibitor 66 Chronic Hepatitis B 66 Severe Sepsis 66 Cardiac Function 66 Capsules CII 66 Randomized Comparison 66 Significantly Improved 66 Osteoporosis Drug 66 Romidepsin 66 Doxil ® 66 Brain Metastases 66 ara C 66 Therapeutic Efficacy 66 Viral Load 66 Therapeutic Potential 66 Rotavirus Vaccine 66 administered subcutaneously 66 HDAC Inhibitor 66 Novel Antibiotic 66 Placebo Controlled 66 Antipsychotic 66 Budesonide 66 melphalan prednisone 66 ORENCIA ® 66 Fulvestrant 66 IND Application 66 Long Term Outcomes 66 Mg Uk 66 Hormone Receptor Positive 66 Primary Endpoint 66 colesevelam HCl 66 Efficacy Trial 66 Receptor Agonist 66 Safinamide 66 alpha 2a 66 Pegylated Liposomal Doxorubicin 66 Mg Usa 66 Dapagliflozin 66 Chemotherapeutic Agents 66 Dose Ranging Study 66 Hepatocellular Carcinoma 66 Neuroprotective Effects 66 Anthracycline 66 Hemolysis 66 Dual Antiplatelet Therapy 66 Molecular Weight Heparin 66 Golimumab 66 efavirenz EFV 66 Corticosteroid 66 Stent Restenosis 66 Lung Cancer Patients 66 Cell Lymphoma 66 Septic Shock 66 Chronic Renal Failure 66 Chronic Myeloid Leukemia 66 Present Preclinical Data 66 Relapsed 66 BARACLUDE ® 66 Infliximab 66 Interferon Gamma 66 Viral Suppression 66 Nucleoside 66 Traficet EN 66 Receives Orphan Drug Designation 66 Castration Resistant Prostate Cancer 66 Initiate Phase 66 Osteoporosis Treatment 66 Randomized Study 66 Bosentan 66 Relapsed Refractory Multiple Myeloma 66 Antitumor 66 Pulmonary Arterial Hypertension 66 Diabetic Nephropathy 66 Fludarabine 66 Glycemic Control 66 5 FU leucovorin 66 Disease Modifying 66 MEK Inhibitor 66 Secondary Hyperparathyroidism 66 Desvenlafaxine Succinate 66 INCB# [003] 66 Eszopiclone 66 Treatment Naive 66 Platinol ® 66 Prostate Cancer Patients 66 TNF Tumor Necrosis Factor 66 Demonstrate Significant 66 Dose Escalation Study 66 Lupus Drug 66 Phase III Pivotal Trial 66 Beneficial Effects 66 Loading Dose 66 Increased Mortality 66 ACTEMRA TM 66 Seasonal Allergic Rhinitis 66 Advanced Pancreatic Cancer 66 Epratuzumab 66 Gemcitabine 66 Prophylactic Treatment 66 analgesic efficacy 65 Node Positive 65 adalimumab Humira 65 Toxicities 65 Etanercept 65 Cognitive Function 65 Immune Responses 65 Anti TNF 65 Fluticasone 65 #mg BID [003] 65 Bosutinib 65 Severe Asthma 65 Telithromycin 65 Pharmacokinetic Profile 65 Moxifloxacin 65 Sapacitabine 65 Non Responders 65 Treatment Naïve 65 Neoadjuvant 65 Dasatinib 65 Rivaroxaban 65 administered concomitantly 65 First Patient Dosed 65 Danazol 65 Reduced Incidence 65 briakinumab 65 Carboplatin Paclitaxel 65 Tocilizumab 65 Postmenopausal Osteoporosis 65 Combination REOLYSIN R 65 Attenuates 65 Physical Function 65 Pafuramidine 65 sunitinib Sutent ® 65 Drug Shows Promise 65 Lamotrigine 65 Hemodialysis Patients 65 Clinical Trial Data 65 Blood Pressure Drug 65 Schizophrenia Drug 65 Randomized Phase II 65 abacavir Ziagen 65 Aurora Kinase 65 CYPHER R Sirolimus Eluting 65 Follicular Lymphoma 65 Newly Diagnosed 65 Drug Combo 65 FASLODEX 65 Allergic Rhinitis 65 abacavir lamivudine 65 Acute Pancreatitis 65 Lung Cancer Trial 65 Pegasys ® 65 Unresectable 65 Ribavirin 65 Novel Inhibitor 65 Chemoradiation 65 posaconazole 65 Kinase Inhibitor 65 PEGylated Fab fragment 65 erlotinib Tarceva ® 65 Teriflunomide 65 Paclitaxel Carboplatin 65 Hepatic Encephalopathy 65 Phase IIa Trial 65 Achieves Primary Endpoint 65 benazepril 65 Pharmacodynamic 65 Tyrosine Kinase Inhibitor 65 Pivotal Trials 65 Vidaza azacitidine 65 Antiangiogenic 65 Clostridium difficile Infection 65 Spectrum Pharmaceuticals Announces 65 Randomized Controlled 65 CANCIDAS 65 RNAi Therapeutic 65 Allogeneic 65 sorafenib Nexavar 65 Atypical Antipsychotic 65 Enlarged Prostate 65 Lupus Nephritis 65 Diabetic Foot Ulcer 65 Myelodysplastic Syndrome MDS 65 TNF Blockers 65 Serious Infections 65 Percutaneous Tibial Nerve Stimulation 65 Telbivudine 65 Gout Drug 65 Itraconazole 65 Preclinical Efficacy 65 FDA Okays 65 Trastuzumab 65 Effectively Treats 65 Migraine Drug 65 HuMax EGFr 65 Xeloda ® 65 FDA Accepts 65 TLUS 65 ST Segment Elevation 65 Thrombotic 65 Exacerbation 65 candesartan cilexetil 65 Treatment Resistant 65 Sirolimus Eluting Stent 65 Treatment Experienced 65 Patency 65 Irinotecan 65 Tipranavir 65 Cardiovascular Outcomes 65 Hemoglobin Levels 65 Initiates Clinical Trial 65 Certolizumab 65 Mycophenolate Mofetil 65 Novel Compound 65 Acute Myocardial Infarction 65 Ropinirole 65 Shows Promise Against 65 Obese Patients 65 Invasive Breast Cancer 64 Data Suggest 64 Significantly Improves 64 Skeletal Muscle 64 Darusentan 64 Cholesterol Levels 64 Atopic Dermatitis 64 Ophena TM 64 interferon alfa 2b 64 B Cell Lymphoma 64 Significantly Reduces 64 Sustained Release 64 C Reactive Protein 64 Atypical Antipsychotics 64 Antidepressant Drug 64 HMG CoA reductase inhibitors 64 ribavirin USP 64 C1 Inhibitor 64 Boceprevir 64 Elagolix 64 Mitoxantrone 64 Left Ventricular 64 salmeterol fluticasone 64 Dose Finding 64 Hematological Cancers 64 Bronchodilator 64 Radical Prostatectomy 64 baminercept 64 Initiate Clinical Trial 64 Therapy Reduces 64 Significant Improvement 64 calcipotriene 64 Enzastaurin 64 tolerability 64 Patients Suffering 64 5 Fluorouracil 64 moderate renal impairment 64 Oral Anticoagulant 64 Aflibercept 64 Archexin 64 Osteoarthritis Patients 64 BAL# [002] 64 Oral Formulation 64 HER2 Positive 64 Endothelial Function 64 Eculizumab 64 Beta Blocker 64 Treatment Reduces 64 Vicriviroc 64 Lipid Levels 64 Toremifene 64 Ambrisentan 64 Dexamethasone 64 Vitro Activity 64 Demonstrates Statistically Significant 64 Lung Cancer Drug 64 demonstrated antitumor activity 64 Tablet Formulation 64 Patient Enrollment 64 Lubiprostone 64 Juvenile Idiopathic Arthritis 64 Cypher Sirolimus 64 PEGASYS ® 64 Artery Disease 64 Premature Infants 64 Critically Ill Patients 64 unfractionated heparin UFH 64 Ovarian Cancer Patients 64 1mg 2mg 64 Chronic Constipation 64 mGluR5 NAM 64 Advanced Ovarian Cancer 64 Cytarabine 64 Showed Significant 64 Zoloft sertraline 64 Ziprasidone 64 Hormone Therapy 64 Thromboembolism 64 Randomized Controlled Trial 64 Proves Effective 64 antiviral efficacy 64 mycophenolate mofetil 64 hyperphenylalaninemia HPA due 64 Humanized Anti 64 STELARA ® 64 Secondary Endpoints 64 oxycodone CR 64 Kidney Transplant Recipients 64 Epilepsy Drug 64 Malignant Melanoma 64 ALVESCO 64 Increased Risk 64 Vivo Efficacy 64 Laquinimod 64 Carbidopa Levodopa 64 nicardipine 64 KRN# 64 4mg/kg 64 Osteoporosis Drugs 64 ST Elevation Myocardial 64 Enzyme Replacement Therapy 64 STELARA TM 64 Depressive Symptoms 64 CIMZIA R 64 Beta Blockers 64 bone marrow reticulin deposition 64 Drug Eluting 64 Tumor Progression 64 Inflammatory Markers 64 Taxotere ® 64 brand ciclesonide HFA 64 hematological parameters 64 Sirolimus Eluting 64 evaluating tivozanib 64 Mylan Receives Approval 64 Pharmacokinetic PK 64 Eltrombopag 64 Contrast Agents 64 Plaque Psoriasis 64 Commonly Used 64 Submits NDA 64 Low Density Lipoprotein Cholesterol 64 DOXIL 64 Intravenous Formulation 64 Fewer Side Effects 64 Prospective Randomized Trial 64 Maribavir 64 Localized Prostate Cancer 64 Cognitive Impairment 64 Lamivudine 64 Pralatrexate 64 Gastrointestinal Stromal Tumors 64 Generic Version 64 Monoclonal Antibody 64 Tolvaptan 64 Oral Cladribine 64 Immunomodulatory 64 Adenoma 64 PRTX 64 pharmacokinetics PK 64 thalidomide Thalomid 64 Targeted Therapy 64 Successfully Treated 64 Intranasal 64 Presents Preclinical 64 Ischemic Stroke 64 relapsed MM 64 Pharmacokinetic Pharmacodynamic 64 mapatumumab 64 PEG IFN 64 metastatic malignant 64 Oritavancin 64 Liposomal 64 INVEGA ® 64 Orthostatic Hypotension 64 Bicalutamide 63 dual endothelin receptor antagonist 63 FDA Clears 63 Shows Statistically Significant 63 LENALIDOMIDE 63 Nymox NX 63 Erectile Dysfunction Drug 63 Adjunctive 63 TAXUS Liberte Long 63 Vaccine Adjuvant 63 ATACAND 63 galiximab 63 acitretin 63 Fenofibrate 63 Aortic Stenosis 63 5 fluorouracil leucovorin 63 Phase 2a Study 63 Emerging Therapies 63 Novel Treatments 63 Xelox 63 Levels Linked 63 Acute Heart Failure 63 Randomized Controlled Trials 63 Topiramate 63 Tumor Growth 63 Endometrial Cancer 63 Lanthanum Carbonate 63 Hepatitis B Vaccine 63 Hyperlipidemia 63 Tigecycline 63 Diabetic Foot Ulcers 63 fosbretabulin 63 Effective Than 63 Breast Cancers 63 FOLFIRI 63 Demonstrates Potential 63 Methotrexate 63 Tasimelteon 63 Cethromycin 63 Radiofrequency Ablation 63 Dosed 63 Acute Attacks 63 Oxybutynin 63 Complete Remission 63 Granted Orphan Drug 63 Teva Provides Update 63 Interferon beta 1b 63 Panzem R 63 certolizumab 63 efficacy tolerability 63 Myelofibrosis 63 TRANSFORMS 63 R lenalidomide 63 Acetate Rectal Suppositories 63 BENICAR HCT 63 Psoriasis Patients 63 Candesartan 63 Factor Receptor 63 Montelukast 63 Sangamo BioSciences Announces 63 Aripiprazole 63 Vaginal Gel 63 rosuvastatin #mg 63 Eluting Stent 63 Retreatment 63 Bone Metastases 63 Squamous 63 Non inferiority 63 APTIVUS 63 Uric Acid 63 Fast Track Status 63 dapagliflozin plus 63 Liver Failure 63 Lung Function 63 Oral Insulin 63 lopinavir r 63 Inhibits 63 Oral Mucositis 63 Neoadjuvant Chemotherapy 63 Peginterferon alfa 2a 63 Sevelamer 63 Comorbidities 63 Clinical Study 63 Valsartan 63 Blood Pressure Lowering 63 SPIRIVA ® 63 piroxicam 63 peginterferon alpha 2a 63 Hepatotoxicity 63 primary hypercholesterolemia 63 Zorbtive TM 63 Darunavir 63 Metastatic Disease 63 CIMZIA ™ 63 Carotid Stenting 63 ocular formulation 63 Long Term Survival 63 SPRYCEL ® 63 Indomethacin 63 Therapy Improves 63 Peginterferon alfa 2b 63 Expanded Indication 63 FDA Approves 63 Adenoma Prevention 63 Liver Metastases 63 Renal Insufficiency 63 Subcutaneous 63 Significant Reduction 63 dasatinib Sprycel ® 63 Asymptomatic 63 Postmarketing 63 pharmacodynamic PD 63 Prostate Cancer Recurrence 63 Anticancer Drugs 63 Vaccine Candidate 63 Potent Anti 63 Receptor Antagonists 63 Slow Progression 63 Pazopanib 63 Gefitinib 63 Sipuleucel T 63 MYCAMINE 63 Blind Placebo Controlled Trial 63 R pioglitazone HCl 63 Pneumococcal Vaccine 63 serum phosphorous 63 Prognostic Value 63 Randomized Trials 63 Elevated Levels 63 pegylated liposomal doxorubicin 63 Metabolic Efficiency 63 teriflunomide 63 AZILECT 63 Tanespimycin 63 Ezetimibe 63 tolerability profile 63 Prophylaxis 63 Fidaxomicin 63 FOLFOX4 63 PEGINTRON TM 63 Post Operative 63 Gene Mutation 63 Postmenopausal 63 Atypical Hemolytic Uremic Syndrome 63 Immunosuppression 63 interferon gamma 1b 63 Predict Risk 63 Myocardial Perfusion Imaging 63 Prostatic 63 Inhalation Aerosol 63 ZOLINZA 63 Lung Cancer Survival 63 Paclitaxel Eluting 63 TRAIL R1 63 docetaxel Taxotere ® 63 FOLPI 63 Epidermal Growth Factor Receptor 63 Initiates Phase 63 Antiviral Therapy 63 atazanavir sulfate 63 Phase III Clinical Trials 63 adalimumab 63 SABCS 63 favorable pharmacokinetic profile 63 Omacetaxine 63 Sym# 63 Antiplatelet 63 Percutaneous Coronary Intervention 63 Extended Release Formulation 63 aripiprazole Abilify 63 urate lowering 63 pioglitazone HCl 63 CIMZIA TM 63 Salmeterol 63 Bezielle 63 pharmacokinetic interactions 63 Replacement Therapy 63 Significant Improvements 63 tolterodine ER 63 Romiplostim 63 MDS MPD 63 VAPRISOL 63 selective modulator 63 Interferon Alpha 63 pharmacokinetic PK 63 Chronic Lymphocytic Leukemia 63 FEMALES SHOULD BE ADVISED 63 First Patient Enrolled 63 Renal Artery 63 EGFR HER2 63 CLINICAL STUDIES 63 Prospective Multicenter 63 amprenavir 63 Initiates Clinical 63 gemcitabine Gemzar 63 Bazedoxifene 63 Microplasmin 63 Induction Therapy 63 aspirin clopidogrel 63 HDL Cholesterol 63 Drug Fails 63 Sandostatin R 63 Cholesterol Drug 62 Ozarelix 62 Malignancies 62 Coronary Stent 62 Cholesterol Drugs 62 Atomoxetine 62 Betaferon R 62 miconazole Lauriad ® 62 Patient Outcomes 62 moderate hepatic impairment 62 Mesalamine 62 2 methoxyestradiol 62 Drug Resistant 62 PEGylated interferon beta 1a 62 Antifungals 62 preclinical efficacy 62 Hepatic 62 riociguat 62 Metformin HCl 62 Clinical Outcomes 62 Azacitidine 62 Known hypersensitivity 62 Taxane 62 fluvastatin 62 Alendronate 62 Functional Outcomes 62 Darinaparsin 62 refractory chronic lymphocytic 62 Unstable Angina 62 dexamethasone Decadron 62 Rheumatoid Arthritis Drug 62 LDL Cholesterol 62 Initiates Phase III 62 Randomised Trial 62 FDA APPROVES 62 coadministration 62 Endovascular Treatment 62 Abciximab 62 azilsartan medoxomil 62 glatiramer acetate 62 octreotide acetate 62 Vertebral Compression Fractures 62 CTAP# Capsules 62 PKC# 62 Tesamorelin 62 myelodysplastic myeloproliferative diseases 62 Ranibizumab 62 Chronic HCV 62 Carbamazepine 62 Gene Variant 62 Small Molecule 62 Randomised 62 pharmacodynamic properties 62 Proven Effective 62 Dosing Regimen 62 oral rivaroxaban 62 Intracranial Aneurysms 62 Combination Vaccine 62 Initiates Enrollment 62 Disease Severity 62 leukopenia pancytopenia thrombocytopenia 62 divalproex sodium 62 Increases Risk 62 Tyrosine Kinase Inhibitors 62 ® lenalidomide 62 prucalopride 62 Interferon Alfa 62 Acute Coronary Syndromes 62 Anti Inflammatory 62 novel VDA molecule 62 Nitazoxanide 62 rNAPc2 62 B Cell Malignancies 62 Anticoagulants 62 Brentuximab Vedotin SGN 62 Arthritis Drug 62 lanthanum carbonate 62 Multicenter Randomized Double 62 headache nasopharyngitis 62 lamotrigine Lamictal 62 complement inhibitor eculizumab 62 Estrogen Therapy 62 betamethasone dipropionate 62 FOLFOX6 chemotherapy regimen 62 Telmisartan 62 Tumor Response 62 Docetaxel 62 tenofovir emtricitabine 62 Squamous Cell Carcinoma 62 Zoraxel 62 alfuzosin 62 Gemzar ® 62 Ritonavir 62 Premenopausal Women 62 APTIVUS r 62 Voreloxin 62 Albuferon TM 62 fluticasone furoate 62 Confirmatory Phase 62 Linagliptin 62 NPH insulin 62 investigational oral inhibitor 62 mg BID 62 Systemic Sclerosis 62 Gastric Cancer 62 Prostate Cancer Progression 62 Intracerebral Hemorrhage 62 Generic Versions 62 Newly Diagnosed Patients 62 Reduces Mortality 62 Methylnaltrexone 62 Preterm Infants 62 Tumor Necrosis Factor 62 TYGACIL 62 liposomal amphotericin B 62 GLYX 62 Neovascular Age Related Macular 62 Antipsychotic Medications 62 Patients Enrolled 62 RoACTEMRA 62 FDA Clearance 62 Demonstrates Sustained 62 Dendritic Cells 62 Files IND 62 Hepatitis C Virus 62 Topical Gel 62 Restenosis 62 budesonide pMDI 62 Pivotal Clinical Trial 62 Treating Heart Failure 62 AEGR 62 Perforomist TM Inhalation Solution 62 Higher Doses 62 Diabetic Neuropathic Pain 62 INFERGEN 62 tigecycline 62 tiotropium bromide 62 Paliperidone Palmitate 62 sertraline Zoloft 62 Vidofludimus 62 Interferon alfa 62 inhaled corticosteroid ICS 62 icatibant 62 BARACLUDE R 62 venlafaxine Effexor 62 Postherpetic Neuralgia 62 Cytotoxicity 62 Preclinical Models 62 lexidronam injection 62 topoisomerase II inhibitor 62 Multicenter Study 62 plus methotrexate 62 mg TID